We take our cues from nature to mimic the physical properties of vegetables. We’re developing biomimetic hydrogel therapies for obesity and other chronic metabolic diseases.
In April 2019, Gelesis received FDA clearance for its lead product candidate, Plenity®, as an aid for weight management in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m², when used in conjunction with diet and exercise. Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. Plenity is currently available in limited release in the U.S.
Gelesis’ proprietary approach inspired to structurally mimic vegetables is designed to act mechanically in the GI pathway to potentially alter the course of certain chronic diseases. In addition to Plenity, Gelesis is developing additional investigational candidates such as Gelesis200, a hydrogel optimized for weight loss and glycemic control in patients with type 2 diabetes and prediabetes. This biomimetic hydrogel based on the Gelesis platform technology are also being advanced in other GI inflammatory conditions, such as non-alcoholic steatohepatitis (NASH) and functional constipation.
Community guidelines: http://bit.ly/2Q8VfUG
In April 2019, Gelesis received FDA clearance for its lead product candidate, Plenity®, as an aid for weight management in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m², when used in conjunction with diet and exercise. Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatin, or titanium dioxide. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. Plenity is currently available in limited release in the U.S.
Gelesis’ proprietary approach inspired to structurally mimic vegetables is designed to act mechanically in the GI pathway to potentially alter the course of certain chronic diseases. In addition to Plenity, Gelesis is developing additional investigational candidates such as Gelesis200, a hydrogel optimized for weight loss and glycemic control in patients with type 2 diabetes and prediabetes. This biomimetic hydrogel based on the Gelesis platform technology are also being advanced in other GI inflammatory conditions, such as non-alcoholic steatohepatitis (NASH) and functional constipation.
Community guidelines: http://bit.ly/2Q8VfUG
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $247.5M
Founded date: 2006
Investors 4
| Date | Name | Website |
| - | LaunchCapi... | launchcapi... |
| 06.11.2022 | Hercules C... | htgc.com |
| - | OrbiMed | orbimed.co... |
| - | Vitruvian ... | vitruvianp... |
Funding Rounds 6
| Date | Series | Amount | Investors |
| 18.11.2021 | - | $30M | - |
| 09.12.2019 | - | $84M | - |
| 02.03.2018 | - | $30M | - |
| 18.12.2015 | - | $31.5M | - |
| 26.03.2015 | IPO | $60M | - |
| 16.05.2014 | - | $12M | - |
Mentions in press and media 35
| Date | Title | Description |
| 18.11.2021 | Gelesis Receives $30 Million Plenity® Order from Ro | - |
| 18.11.2021 | PureTech Founded Entity Gelesis Receives $30 Million Plenity® Order from Ro | PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company, announced today that its Founded Entity, Gelesis, Inc. (“Gelesis”) received a $30 million fully paid pre-order for the co... |
| 18.11.2021 | Gelesis Receives $30 Million Plenity Order from Ro | Gelesis announced today that leading U.S. direct-to-patient healthcare company Ro has placed a $30 million fully paid pre-order for the company’s first commercial product for weight management, Plenity®. Plenity was initially made available... |
| 01.10.2020 | Ro makes the weight loss product Plenity commercially available to everyone in the US | In what could be the first step in the development of a significant new line of business for the telemedicine prescription provider Ro, the company is finally announcing the general commercial availability of weight loss product, Plenity. D... |
| 09.12.2019 | Gelesis Secures Over $84M | BOSTON, MA, Gelesis announced it secured $84.6 million in new capital led by private equity firm Vitruvian Partners. >> Click here for more funding data on Gelesis >> To export Gelesis funding data to PDF and Excel, click he... |
| 09.12.2019 | Gelesis Secures Over $84 Million in New Capital | BOSTON--(BUSINESS WIRE)--Gelesis, a biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, today announced it secured $84.6 million in ne... |
| 09.12.2019 | Gelesis Raises Over $84M in Funding | Gelesis, a Boston, MA-based biotechnology company developing a novel hydrogel platform technology to treat obesity and other chronic diseases related to the gastrointestinal (GI) tract, secured $84.6m in funding. Vitruvian Partners led a $6... |
| 09.12.2019 | Biotech startup Gelesis raises over $84 million to support the U.S. launch of Plenity, a drug for treatment of obesity and other gastrointestinal chronic diseases | The prevalence of obesity was 39.8% and affected about 93.3 million of US adults in 2015~2016, according to data from U.S. Centers for Disease Control and Prevention (CDC). Gelesis is a Boston-based biotech startup developing therapeutics t... |
| 09.12.2019 | Top tech startup news for today, Monday, December 9, 2019 – Amazon, FlexPay, Centana, WalkMe | Good morning! Below are some of the top tech startup news for today, Monday, December 9, 2019. Amazon is blaming President Trump for losing $10 billion JEDI cloud contract to Microsoft. Let the blame game begins. Amazon Web Services (AWS),... |
| 02.03.2018 | Gelesis raises $30M to gear up for weight loss launch | Gelesis has raised $30 million as it prepares to file for approval of its weight loss device. The financing equips Gelesis to get its manufacturing and commercial arms ready for launch should regulators look favorably on its mixed late-phas... |
Show more